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Huntington’s disease (HD) is a neurodegenerative disor-
der caused by an elongation of CAG repeats in the HD
gene, which encodes a mutant copy of huntingtin with
an expanded polyglutatmine repeat. Individuals who
are affected by the disease suffer from motor, cogni-
tive, and emotional impairments. Levels of certain stria-
tal-enriched mRNAs decrease in both HD patients and
transgenic HD mice prior to the development of motor
symptoms and neuronal cell death. Ciliary neurotrophic
factor (CNTF) has been shown to protect neurons
against chemically induced toxic insults in vitro and
in vivo. To test the hypothesis that CNTF might protect
neurons from the negative effects of the mutant hun-
tingtin protein in vivo, CNTF was continuously
expressed following transduction of the striatum by
recombinant adeno-associated viral vectors (rAAV2).
Wild-type and R6/1 HD transgenic (R6/1) mice that
received bilateral or unilateral intrastriatal injections of
rAAV2-CNTF experienced weight loss. The CNTF-
treated R6/1 HD transgenic mice experienced motor
impairments at an earlier age than expected compared
with age-matched control R6/1 HD transgenic animals.
CNTF also caused abnormal behavior in WT mice. In
addition to behavioral impairments, in situ hybridization
showed that, in both WT and R6/1 mice, CNTF expres-
sion caused a significant decrease in the levels of stria-
tal-enriched transcripts. Overall, continuous expression
of striatal CNTF at the dose mediated by the expres-
sion cassette used in this study was detrimental to HD
and wild-type mice. VC 2008 Wiley-Liss, Inc.
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Huntington’s disease (HD) is an inherited neurode-
generative disorder, characterized by progressive decline
in motor and cognitive ability and emotional disturban-
ces (Huntington’s Disease Collaborative Research
Group, 1993). HD results from inheritance of one copy
of the HD gene with more than 36 CAG repeats within
the polymorphic CAG repeat locus in exon 1. CAG tri-
plet repeats are translated into polyglutamine (PolyQ),
and the extended polyglutamine tract in mutant hun-
tingtin leads to a conformational change in huntingtin
protein resulting in a protein that is toxic to a subpopu-
lation of neurons, especially the medium-sized spiny
neurons that reside in the caudate and putamen (Walling
et al., 1998). In the early stages of the disease, patients
may show symptoms without significant loss of cells,
suggesting that neuronal dysfunction precedes cell death
(Young et al., 1986; Sharp et al., 1995). In fact, mutant
huntingtin expression disrupts the regulation of basal
neuronal transcriptional activity in both presymptomatic
HD transgenic mice and HD patients (Cha, 2000;
Luthi-Carter et al., 2000, 2002; Naver et al., 2003; Sug-
ars and Rubinsztein, 2003; Hebb et al., 2004; Hu et al.,
2004; Li and Li, 2004; McCaw et al., 2004; Desplats
et al., 2006; Gomez et al., 2006; Hodges et al., 2007;
Kuhn et al., 2007), and, even without a thorough
understanding of how decreases in specific mRNAs and
proteins impact disease progression in HD, monitoring
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the levels of specific mutant huntingtin-affected mRNAs
provides a potential method for quantifying the thera-
peutic benefits of pharmacological agents.
Ciliary neurotrophic factor (CNTF) is a growth
factor that promotes the growth, differentiation, and sur-
vival of neurons (Hefti, 1997). The binding of CNTF to
its receptor results in changes in intracellular signaling
pathways. The receptor for CNTF is a trimer composed
of leukemia inhibitory factor receptor b, glycoprotein
130, and a CNTF-specific a receptor (Neet and Campe-
not, 2001). CNTF binds specifically to the CNTF-spe-
cific a receptor, which in turn leads to the activation of
Janus tyrosine kinase. Members of the signal transduction
activator of transcription (STAT) family of transcription
factors are phosphorylated and activated due to the acti-
vation of Jak kinases (Neet and Campenot, 2001). Prior
to activation by CNTF, the STAT proteins are located
in the cytoplasm. However, after binding of CNTF, the
STAT proteins are translocated to the nucleus. This new
signaling cascade targets the nucleus, ultimately resulting
in changes in gene expression (Segal and Greenberg,
1996; Bonni and Greenberg, 1997).
CNTF and other trophic factors have been consid-
ered potential therapeutic treatments for a wide range of
nervous system disorders (Emerich and Thanos, 2006).
In vitro studies with CNTF demonstrated that it sup-
ports the survival of parasympathetic neurons from the
chick ciliary ganglia (Adler et al., 1979; Arakawa et al.,
1990; Sendtner et al., 1990). Further studies have shown
that CNTF also has trophic effects on other populations
of central and peripheral neurons (Bachoud-Levi et al.,
2000; Vergara and Ramirez, 2004). In 2000, Mittoux
et al. implanted baby hamster kidney (BHK) cells that
were engineered to secrete CNTF into an excitotoxin-
lesioned animal model that reproduces the pattern of cell
loss observed in HD. They found that delivering low
doses of CNTF intracerebrally protected neurons from
degeneration and restored neostriatal function in neuro-
toxin-induced models (Mittoux et al., 2000; Emerich,
2004; Emerich and Winn, 2004). However, several stud-
ies have documented that rodents as well as humans
receiving systemic delivery of CNTF experience weight
loss (Henderson et al., 1994; Miller et al., 1996; Ettinger
et al., 2003; Kokoeva et al., 2005).
We chose, based on the previously documented
neuroprotective effects of CNTF in vitro and in vivo, to
administer CNTF into the striatum of R6/1 HD trans-
genic mice. We hypothesized that continuous intrastria-
tal administration of CNTF in this genetic model of HD
could potentially preserve the function of striatal neu-
rons, which are particularly susceptible to the toxic
effects of mutant huntingtin. To observe the effects of
chronic administration of CNTF on cells in the striatum,
a recombinant adeno-associated viral vector was engi-
neered to express a secretable form of CNTF and pack-
aged into viral particles (rAAV2-CNTF). rAAV vectors
have been selected for use in the CNS because of their
inherent safety and neurotropism (Mandel et al., 2006).
These replication-deficient viral vectors can efficiently
deliver genetic cargo into defined brain regions such as
the striatum. AAV2-based viral vectors preferentially
transduce striatal neurons (Burger et al., 2004; Taymans
et al., 2007) when delivered to the parenchyma of the
striatum and provide for continuous production of the
transgene throughout the life of the animal (Mandel
et al., 2006). Moreover, a single striatal injection of
rAAV2 vector does not lead to chronic changes in gene
expression profile, striatal pathology, weight loss, or
abnormal behavior (Mandel et al., 1998; Kirik et al.,
2000; Peden et al., 2004; Rodriguez-Lebron et al.,
2005; Denovan-Wright et al., 2007; Herzog et al.,
2007). Therefore, this vector system seems ideal to study
continuous delivery of trophic factors in mouse models
of neurological disorders.
Given that CNTF and other trophic factors have
shown neuroprotective effects in cell culture and in
excitotoxic lesion models of HD, our goal was to deter-
mine whether rAAV2-mediated CNTF could protect
striatal neurons from the toxic effect of the N-terminal
of mutant huntingtin expressed in a transgenic model of
HD, which more closely resembles the human disease
than lesion models. It is known that the detrimental
effects of mutant huntingtin on neurons throughout the
brain precede selective degeneration seen in the caudate
and putamen (Smith et al., 2006). We chose to observe
the effects of sustained CNTF expression on behavioral
phenotype, gene expression, and cell morphology in
R6/1 mice, because this strain is slower to progress, has
a later onset of motor abnormalities, and has a longer life
span than the R6/2 strain (Mangiarini et al., 1996).
Importantly, these mice have alterations in gene expres-
sion and phenotype but do not show significant neuro-
degeneration (Naver et al., 2003; Hodges et al., 2007).
Overall, we found that CNTF negatively affected the
behavior and intrastriatal gene expression of wild-type
(WT) and HD transgenic mice.
MATERIALS AND METHODS
Animals
Transgenic R6/1 male mice were originally purchased
from Jackson Laboratories (Bar Harbor, ME). A colony was
maintained by crossing hemizygous R6/1 males from within
the colony back with CBA 3 C57BL/6 females, and each
animal was genotyped as described previously (Gomez et al.,
2006). Animal care and handling followed the guidelines of
the Canadian Council on Animal Care and were approved by
the Carleton Animal Care committee at Dalhousie University.
Every effort was made to minimize the number of animals
used in this study and to minimize their discomfort.
Expression of rAAV2-Encoded CNTF
Gene in R6/1 Mice
The complete coding region for recombinant human
CNTF fused to the human growth hormone signal peptide
for secretion (Bok et al., 2002) was PCR amplified using pri-
mers containing HindIII/NsiI sites and introduced into the
multiple cloning site of the pTR-UF12-IRES-GFP plasmid
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under the regulation of a chicken b-actin promoter. This
strategy resulted in a bicistronic transgene that produced both
CNTF and GFP because of the presence of an internal ribo-
somal entry site (IRES) element between both coding sequen-
ces. rAAV2 vector coding for CNTF was produced and puri-
fied at the Gene Therapy Center Vector core facility at the
University of Florida as described previously in detail (Zolotu-
khin et al., 2002). Briefly, 293 cells were cotransfected with
pDG (a plasmid containing all required adenoviral genes and
rep and cap) and pTR-UF12-CNTF (described above). The
cells were lysed, and the supernatant was purified using an
iodixenol gradient, followed by a hand-packed heparin col-
umn. The purified virus was then dialyzed such that the final
stock contained only rAAV and phosphate-buffered saline.
The vector was titered using a dot blot for vector genomes.
The rAAV2-UF12-CNTF virus was 2.7 3 1012 vector
genomes/ml. The vector rAAV2-UF11, which expresses only
GFP, was used as a control, and this virus was 4.2 3 1011 ge-
nome copies/ml (Burger et al., 2004).
Mice were anesthetized with isoflurane and rAAV2-
CNTF (1 ll) was stereotaxically injected in the right striatum
via a pulled-glass pipette. The intrastriatal injections for the
mice were delivered at a rate of 0.5 ll/min into the right
striatum at the following coordinates with respect to Bregma
and the surface of the brain: anterior posterior (AP) 10.9
mm, lateral (Lat) 22.0 mm, dorsal ventral (DV) 23.3 mm.
Bilaterally injected mice received 1 ll of rAAV2-CNTF into
the left and right striatum [(AP) 10.9 mm, (Lat) 62.0 mm,
and (DV) 23.3 mm]. After the delivery of the rAAV2-
CNTF, there was a 1 min delay before the pipette was slowly
raised to a new DV coordinate of 23.0 mm to allow the vec-
tor to diffuse into the tissue. The glass pipette was left in place
(DV 5 23.0 mm) for an additional 2 min before being
slowly withdrawn. All animals received a single intraperitoneal
injection of the long-lasting analgesic ketoprofen (2 mg/kg)
prior to regaining consciousness.
Four weeks after surgery, the mice in the unilaterally
injected treatment group were deeply anesthetized by intra-
peritoneal injection of 65 mg/kg sodium pentobarbital and
decapitated, and the brains were removed and frozen at
2708C. Coronal sections of the brain (14 lm) were cut on a
cryostat through the rostral-caudal axis of the striatum and
placed on Fisherbrand Superfrost slides. Five sections were
placed on each slide such that the sections on each slide repre-
sented regions of the striatum separated by 350 lm. The
sections were used for in situ hybridization analysis of the lev-
els of mRNA. Genbank accession numbers for all of the
hybridization probes, with the exception of those used to
detect dynamin and GFP mRNA, have been documented
by Rodriguez-Lebron et al. (2005). The dynamin oligonu-
cleotide (50-CACTGGCTTTCTCTTTGTCCCCAACAC
GCTC-30) was complementary to nts 1943–1973 of the
mouse Mus musculus dynamin 1 cDNA (Genbank accession
No. NM_010065), whereas the GFP oligonucleotide (50-
GGCGGAGCGGGGCACGGGGCGAAGGCAGCG-30) was
complementary to nts 485–514 of the Expression vector pGI-
pec, partial sequence (Genbank accession No. AF4282). The
methods for in situ hybridization, cresyl violet staining, and
immunohistochemical analysis using Hum-1 antibody were
performed on coronal sections of the mice that received uni-
lateral injections of rAAV2-CNTF, described previously
(Rodriguez-Lebron et al., 2005). mRNA levels were analyzed
in Kodak 1D Image Analysis software. The optical density of
the hybridization signal for each mRNA and each animal was
normalized by subtracting the local slide background. The op-
tical density of the corrected hybridization signal was sub-
jected to two-way ANOVA assessing the influence of geno-
type and treatment of independent groups of mice. A 0.05
level of significance was adopted for all comparisons. ELISA
was employed to determine levels of human CNTF in the
injected striatum of each mouse following transduction by
rAAV2-CNTF. Tissue from 10 sections of the injected and
uninjected striata of each unilaterally injected mouse was iso-
lated from the slides and homogenized in PBS containing pro-
tease inhibitor (Complete Mini protease inhibitor cocktail tab-
lets; Roche, Indianapolis, IN). The concentration of protein
in each sample was determined by BCA (Bio-Rad, Hercules,
CA). Levels of CNTF were quantified using the Quantikine
human CNTF ELISA Assay (R&D Systems, Minneapolis,
MN). The ratio of CNTF (pg)/total protein (mg) was calcu-
lated and subjected to two-way ANOVA.
Behavioral Assessment
The bilaterally injected mice were observed over a 6-
week period following injection of rAAV2-CNTF. Behavioral
analysis was done on a weekly basis by a technician who was
blind to the genotype and treatment group of all animals. The
behaviors and phenotype were measured as described by Dit-
zler et al. (2003; see Suppl. Table I). This scoring system is
designed to rate HD-like behaviors in mice and to indicate an
individual mouse’s level of abnormal behavior. Wild-type
mice routinely received a cumulative score of 0.
Statistical Analysis
ANOVA was used to evaluate the probability of differ-
ences between experimental groups. Where appropriate, one-
way ANOVA was performed, and individual post hoc differ-
ences were assessed using Tukey’s honestly significant multiple
comparisons. Student’s t-tests were used where appropriate.
Data are presented as mean 6 SEM. P < 0.05 was used as the
significance threshold throughout the study.
RESULTS
Effect of rAAV-CNTF Administration on
Appearance and Behavior
rAAV2-CNTF was administered bilaterally into the
left and right striata of 10-week-old WT mice (n 5 7,
WT 1 CNTF) and 10-week-old R6/1 HD transgenic
mice (n 5 7, R6/1 1 CNTF). The controls included
untreated WT (n 5 7) and R6/1 HD transgenic (n 5
6) littermates. The difference between the mass of each
mouse at 10 and 16 weeks of age was calculated. Over
the 6-week period, the untreated R6/1 and WT mice
gained on average 1.7 (60.6) and 3.2 (61.0) g, respec-
tively. In contrast, over the same 6-week period, the
rAAV2-CNTF-treated R6/1 and WT mice lost 2.8
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(60.7) and 1.0 (60.8) g, respectively. There was a sig-
nificant difference in change in body mass in the
rAAV2-CNTF-treated WT and R6/1 mice compared
with untreated genotype-matched littermates (P < 0.05).
Intrastriatal administration of rAAV vectors does not
alter body weight or behavior in wild-type or R6 trans-
genic mice (Rodgriquez-Lebron et al., 2005; Denovan-
Wright et al., 2007).
Each mouse was examined for general appearance
and behavior (see Suppl. Table I for scoring) on a
biweekly basis. The individual scores for each measure-
ment (Suppl. Table II) for each mouse were summed,
and the average (6SEM) behavior for mice in different
treatment groups was calculated at 2, 4, and 6 weeks fol-
lowing the date of surgery. Two-way ANOVA con-
firmed a significant treatment by genotype effect (Fig.
1). Two weeks after surgery, the scores of the R6/1 1
CNTF mice showed significantly more abnormal behav-
ior compared with untreated WT mice (P < 0.05). Four
and six weeks after surgery, both the WT 1 CNTF and
the R6/1 1 CNTF mice displayed significantly more
abnormal behavior compared with untreated WT mice
(P < 0.05; Fig. 1). Normally, R6/1 HD transgenic mice
start to show abnormal HD-like phenotypes at 16–20
weeks of age (Mangiarini et al., 1996). As expected,
therefore, there was no significant difference between
untreated WT and untreated R6/1 HD mice at 12, 14,
and 16 weeks of age.
The ability of mice to remain on a bar that has
increasing speed of revolutions over a defined time pe-
riod (rotarod) is often used as a measurement of gross
motor skills (Carter et al., 1999). Rotarod data were col-
lected 2, 4, and 6 weeks after bilateral injection of
rAAV2-CNTF. Two weeks following surgery, there was
no statistically significant difference among mice in dif-
ferent treatment groups (Fig. 2). However, 4 and 6
weeks after surgery, the rAAV2-CNTF-treated R6/1
mice were unable to remain on the rotating bar as long
as untreated WT or R6/1 mice (P < 0.05; Fig. 2).
There was no significant difference in time remaining
on the rotating bar among untreated WT mice, rAAV2-
CNTF-treated WT, and untreated R6/1 mice.
Effects of CNTF on Gene Expression
In a separate experiment, rAAV2-CNTF was
administered unilaterally into the right striata of 15 mice
(WT, n 5 6; R6/1, n 5 9), and the animals were
allowed to survive for 4 weeks. As was observed in the
animals that received bilateral injection of rAAV2-
CNTF, the WT and R6/1 mice that received a unilat-
eral injection of rAAV2-CNTF lost weight (P < 0.05).
The unilateral injection of rAAV2-CNTF allowed for
comparison of mRNA levels in the injected and unin-
jected striata of each animal. Coronal brain sections were
subjected to in situ hybridization to measure the effects
of the rAAV2-CNTF vector on levels of specific brain
transcripts.
The transcript produced by our rAAV2-CNTF
vector contained the open-reading frames for both
CNTF and green fluorescence protein (GFP) in order to
facilitate the identification of positively transduced cells.
Using probes targeting the GFP coding sequence, we
observed localized expression of our AAV2-CNTF tran-
script via in situ hybridization in striatal cells that were
confined to the area in proximity to the site of delivery
Fig. 1. Bilateral intrastriatal injections of rAAV2-CNTF increased
abnormal behaviors in both WT and R6/1 HD transgenic (R6/1)
mice. Black, gray, and white bars are the mean behavior (6SEM) at
2, 4, and 6 weeks, respectively. Two-way ANOVA indicated that
there was a significant treatment effect. One-way ANOVA and
Tukey’s post hoc tests were used to compare between groups. *P <
0.05 vs. untreated wild-type mice at each time point. @P < 0.05 vs.
WT 1 CNTF at 2 weeks within this treatment group. P < 0.05
vs. R6/1 1 CNTF mice at 2 weeks within this treatment group.
Fig. 2. Bilateral intrastriatal injections of rAAV2-CNTF impaired
motor coordination in R6/1 HD transgenic (R6/1) mice 4 and 6
weeks after surgery. Black, gray, and white bars are the mean rotarod
score (6SEM) at 2, 4, and 6 weeks, respectively. One-way ANOVA
was used to compare the mean rotarod score of WT and R6/1 mice
that were untreated or received rAAV2-CNTF (WT 1 CNTF and
R6/1 1 CNTF) at each time point. *P < 0.05 difference from
untreated WT 4 weeks after surgery. @P < 0.05 difference from
untreated WT 6 weeks after surgery.
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(Fig. 3A). The hybridization signal indicated that a sub-
set of cells within each injected striatum had been trans-
duced and was expressing mRNA encoded by the
rAAV2-CNTF vector. Levels of CNTF were quantified
by ELISA. The protein levels that reacted with anti-
human CNTF in ELISA were significantly higher in the
rAAV2-CNTF transduced striatum than the uninjected
striatum of both wild-type and R6/1 mice, but there
was no difference in CNTF levels in the transduced
striatum of wild-type and R6/1 mice (Fig. 3B). The
regional distribution of our rAAV2-CNTF transgene as
determined by in situ hybridization of mRNA encoded
by rAAV2-CNTF vector was compared with the pattern
of expression of other mRNAs that are expressed in the
striatum and cortex. It appeared that, regardless of geno-
type, the expressions of DARPP-32, ppENK, CB1,
PDE1B, PDE10A, NGFI-A, dynamin, and b-actin were
lower in the hemisphere that received rAAV2-CNTF.
Moreover, the decrease in levels of these mRNAs was
not confined to regions that expressed rAAV2-CNTF
mRNA, but rather the decrease appeared to be in cells
throughout a wider region of the injected hemisphere.
Adjacent sections that span the rostral-caudal axis of the
striatum from one representative WT and one R6/1
mouse that were subjected to unilateral injection of
rAAV2-CNTF and in situ hybridization analysis for
GFP, DARPP-32, ppENK, and CB1 mRNA levels are
shown in Figure 3. To control for the effects of adminis-
tration of rAAV2 on gene expression, rAAV2-UF11,
which expressed GFP but not any other protein, was
administered unilaterally to four R6/1 mice. There was
no effect on the expression of DARPP-32, ppENK,
CB1, PDE1B, PDE10A, NGFI-A, and b-actin in the
mice injected with rAAV2-UF11 compared with unin-
jected, age- and genotype-matched mice (Suppl. Fig. 1).
These data demonstrated that the effects on transcription
observed in rAAV2-CNTF-injected animals were caused
by expression of CNTF and not delivery of the viral
vector or expression of GFP.
ppENK and D2 receptor mRNA are expressed by
a subpopulation of medium spiny projection neurons,
and levels of these mRNAs are lower in the striatum of
several transgenic mouse models of HD (Kuhn et al.,
2007). As expected, levels of both these transcripts were
higher in the striatum of uninjected WT mice compared
with the uninjected R6/1 HD transgenic mice (Fig. 4).
Surprisingly, ppENK and D2 mRNA levels were even
lower in the rAAV2-CNTF-treated hemisphere of the
brain compared with the corresponding region in the
untreated side of both WT and R6/1 mice (Fig. 4).
CNTF had a greater proportional effect on ppENK and
D2 mRNA levels in the rAAV2-CNTF-treated R6/1
compared with the treated WT mice.
DARPP-32, PDE1B, and PDE10A are highly
expressed in all medium spiny projection neurons of the
striatum, with lower levels of expression in the cortex
and olfactory tubercle and expression of mutant hunting-
tin lowers levels of these mRNAs (Hebb et al., 2004).
These transcripts were lower in the uninjected striatum
of 16-week-old R6/1 compared with WT mice and
lower in the rAAV2-CNTF-treated hemisphere of each
animal (Fig. 4). As was observed with ppENK and D2
mRNA, it appeared that CNTF affected mRNA levels
of DARPP-32, PDE1B, and PDE10A in cells that were
distributed throughout the striatum and not just those
cells that were directly transduced by the viral vector
(Fig. 3). The proportional decline of DARPP-32 result-
ing from CNTF was greater in the R6/1 mice com-
pared with their WT counterparts. However, the pro-
portional declines of PDE1B and PDE10A are not sig-
nificantly different in the CNTF-treated WT mice
compared with the CNTF-treated R6/1 HD transgenic
mice.
Fig. 3. Injection of rAAV2-CNTF into the striatum leads to expres-
sion of green fluorescent protein (GFP) mRNA encoded by the viral
vector in a small number of striatal neurons. The levels of DARPP-
32, ppENK, and CB1 mRNA in the striatum were affected by
administration of rAAV2-CNTF throughout the treated striatum in
WT and R6/1 transgenic HD mice (R6/1; A). Five coronal sections
from one representative mouse that was unilaterally injected with
CNTF were subjected to in situ hybridization using mRNA-specific
probes as indicated above each set of sections. The coronal sections
on each slide are separated by 350 lm. Transduction of striatal neu-
rons by rAAV2-CNTF increased levels of human CNTF as detected
by ELISA (B). The level of CNTF (pg) was normalized to the con-
centration of total protein in the sample (mg). Error bars indicate 1
SD. *P < 0.05 difference between CNTF and untreated striata.
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CB1 mRNA is expressed in neurons throughout
the brain, with highest levels of expression in neurons in
the lateral striatum (McCaw et al., 2004). Levels of CB1
were found to be higher in uninjected WT compared
with uninjected R6/1 mice (Fig. 4). Levels of CB1
mRNA in the lateral striatum were affected by rAAV2-
CNTF expression in the striatum of WT mice (Fig. 3).
Levels of CB1 mRNA in the lateral striatum of R6/1
HD transgenic mice decline in young R6/1 mice to lev-
els that are uniform throughout the brain (McCaw
et al., 2004) such that further rAAV2-CNTF-dependent
reductions in mRNA levels in the neurons of the lateral
striatum might not have been measurable. There was no
significant difference in the proportional decrease of
CB1 in WT and R6/1 HD transgenic mice.
NGFI-A is expressed at low levels in the cortex as
well as the striatum (Luthi-Carter et al., 2000). Levels of
NGFI-A mRNA were higher in uninjected WT com-
pared with uninjected R6/1 HD transgenic mice (Fig.
4). NGFI-A mRNA levels decreased in the rAAV2-
CNTF-injected striatum of R6/1 HD transgenic mice.
Although NGFI-A is known to decrease in transgenic
HD mice, it can be induced in response to cell stress
and acts as an indicator of inflammatory response or
increased neuronal response to stimuli (MacGibbon
et al., 2002). We did not observe an increase in NGFI-
A mRNA in the cells transduced by rAAV2-CNTF or
in cells adjacent to transduced cells, demonstrating that
CNTF did not induce expression of NGFI-A.
Dynamin is expressed in the motor cortex and the
piriform cortex and is known to decrease in HD
YAC72 mice (Zuccato et al., 2003). We observed a
decline in the levels of dynamin mRNA in the cortex of
rAAV2-CNTF- treated WT and R6/1 HD transgenic
mice (Fig. 4). Similarly, a decrease in the levels of b-
actin mRNA was observed in the rAAV2-CNTF-treated
striatum of both the WT and R6/1 HD transgenic mice
(Fig. 4). There was no significant difference in the pro-
portional decrease of dynamin or b-actin mRNA in
rAAV2-CNTF treated WT and R6/1 HD transgenic
mice. It appeared that the effect of CNTF was not lim-
ited to the striatum that was injected with the viral vec-
tor but was able to affect distal neurons in the cortex
that were ipsilateral to the injected striatum.
Cell Morphology
To determine whether the CNTF-dependent
down-regulation of mRNA levels was due to a loss of
cells, tissue from WT and R6/1 mice that had received
unilateral intrastriatal injections of rAAV2-CNTF were
stained with cresyl violet (Fig. 5). No obvious differen-
ces were noted in the size, morphology, or distribution
of cresyl violet-stained neuronal cell bodies between the
untreated left and rAAV2-CNTF-treated right striata in
WT or R6/1 mice, demonstrating that the neurons
were present following CNTF treatment. An antibody
(Hum 1) that specifically recognizes the amino-terminus
of human mutant huntingtin in NII protein aggregrates
and that cross-reacts with cytoplasmic proteins in striatal
neurons of WT and R6/1 mice (Rodriguez-Lebron
et al., 2005) was also used to determine the relative dis-
tribution of neurons and NIIs following transduction by
rAAV2-CNTF. As was observed using cresyl violet
staining, no difference in the size or distribution of Hum
1-immunoreactive proteins dispersed within neurons or
aggregated in NIIs was observed in animals receiving
rAAV2-CNTF (data not shown).
DISCUSSION
In this study, we assessed the effects of continuous
intrastriatal CNTF expression on the behavior, weight,
and gene expression profile of WT and R6/1 HD trans-
genic mice following transduction of striatal neurons
Fig. 4. Administration of CNTF over 4 weeks decreased levels of
mRNA. rAAV2-CNTF was injected into the right striatum, and the
average optical density (6SEM) of the hybridization signal in the
untreated (solid bars) WT (WT) and R6/1 transgenic HD (R6/1)
and CNTF-treated (striped bars) WT (WT 1 CNTF) and R6/1
(R6/1 1 CNTF; striped bars) striata were calculated for each probe.
*P < 0.05 difference between CNTF-treated and untreated striata of
the same genotype. @P < 0.05 difference between untreated striata
of WT and R6/1 mice.
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with a single injection of rAAV2-CNTF. We hypothe-
sized that intrastriatal delivery of rAAV2-CNTF would
delay the onset of motor abnormalities in R6/1 HD
transgenic mice and slow or prevent mutant huntingtin-
induced decreases in a subset of striatal-enriched
mRNAs. Originally, we planned to observe the mice for
10 weeks following bilateral injections of rAAV2-
CNTF. However, 6 weeks following surgery, these
mice were sacrificed after displaying obvious adverse
effects that were associated with striatal CNTF overex-
pression.
Biweekly weight measurements indicated that the
R6/1 HD transgenic and WT mice that received intra-
striatal CNTF experienced weight loss, whereas
untreated WT and R6/1 mice gained weight over the
same time period. Weight loss was specific to CNTF
overexpression, in that injecting rAAV2 expressing GFP
alone or active ribozymes into the brain of R6/1 mice
does not result in weight loss (Mandel et al., 1998; Kirik
et al., 2000; Peden et al., 2004; Rodriguez-Lebron
et al., 2005; Herzog et al., 2007). CNTF is well known
to induce weight loss through hypothalamic pathways
even in leptin-resistant mice (Lambert et al., 2001), and
systemic delivery in obese humans leads to significant
weight loss (Ettinger et al., 2003). Furthermore, CNTF
can cause proliferation of hypothalamic neurons, and this
may directly change regulation of energy metabolism
and cause weight loss in mice (Kokoeva et al., 2005).
Moreover, in similar gene transfer studies, lentiviral-
mediated delivery of CNTF in the striatum of a rat QA
model of HD led to a reduction in weight gained com-
pared with LacZ-expressing controls (de Almeida et al.,
2001). In contrast to these results, CNTF-dependent
effects on weight were not reported when implants of
encapsulated BHK cells or osmotic minipumps were
used to deliver CNTF to the brain in other chemically
induced models of HD. In more recent studies, how-
ever, systemic or intrathecal delivery of CNTF also
caused weight loss, as well as cachexia, in rodents (Ver-
gara and Ramirez, 2004). It is likely that differences in
administration route, concentration levels, and diffusion
of the delivered CNTF account for its apparent variable
effects on body mass. R6/1 HD transgenic mice do not
gain weight at the same rate as WT littermates (Rodri-
guez-Lebron et al., 2005), and HD patients lose weight
as HD progresses. In fact, HD patients require a substan-
tial increase in caloric intake in order to maintain a con-
stant weight (Trejo et al., 2004). CNTF-induced weight
loss, therefore, would be predicted to be additive to the
HD-induced weight loss and, thus, could be particularly
detrimental to HD patients.
Currently, it is hypothesized that mutant hunting-
tin abnormally interacts with transcriptional machinery,
resulting in transcriptional dysregulation of specific genes
(Sugars and Rubinsztein, 2003). It is not known whether
changes in specific mRNAs are related to symptoms of
HD; however, changes in levels of selected mRNAs can
be followed as markers of HD progression. We predicted
that, if CNTF were acting as a neuroprotective agent to
counter the toxic effects of mutant huntingtin, we might
see a slowing of the loss of these mRNAs, which might
have correlated with a delay in the onset of abnormal
motor phenotype. In situ analysis revealed that mRNA
levels of DARPP-32, ppENK, D2, PDE10A, PDE1B,
NGF1-A, b-actin, and dynamin decreased significantly
throughout the brain hemisphere that received rAAV2-
CNTF in both WT and R6/1 HD transgenic mice.
These transcriptional changes are not observed when
rAAV2 expressing only GFP is injected into the brain of
R6/1 HD transgenics or their WT littermates. Addition-
ally, we found a proportional decline in the levels of
PDE1B, PDE10A, NGFI-A, CB1, dynamin, and b-actin
in WT and R6/1 HD transgenic mice injected with
rAAV2-CNTF. In contrast, the levels of DARPP-32,
ppENK, and D2 decreased to a greater extent in treated
R6/1 HD transgenic compared with treated WT mice.
This suggests that rAAV2-CNTF equally affected the
transcriptional regulation of some genes independent of
mutant huntingtin expression, whereas the expression
levels of a different set of striatal genes was more sensi-
tive to the effects of CNTF in R6/1 than their WT lit-
termate controls. This mutant huntingtin-dependent dif-
ferential effect of CNTF on neuronal gene regulation
has not been previously reported. Our thorough in situ
analysis should help us begin to elucidate the underlying
signaling pathways responsible for mediating these
effects.
Although we observed focal expression of rAAV2-
CNTF mRNA, reduced levels of striatal-enriched gene
expression extended to striatal cells that were at a dis-
tance from directly transduced neurons. This observation
suggested that CNTF was secreted from rAAV2-CNTF
transduced cells and also affected gene expression in a
paracrine fashion. Alternatively, local CNTF-induced
Fig. 5. CNTF did not affect cell number or morphology. Adjacent
coronal sections from WT (WT) and R6/1 HD transgenic (R6/1)
mice that received rAAV2-CNTF in the right striatum were sub-
jected to in situ hybridization with a DARPP-32-specific probe or
stained with cresyl violet (CV). The genotypes of the representative
sections are indicated on the left. The animals were 16 weeks of age.
Photomicrographs of the cresyl violet-stained section from the left
and right striatum are shown. Scale bars 5 20 lm.
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toxic effects might have led to changes in the gene
expression profiles of neighboring or surrounding neu-
rons. Importantly, we did not observe a decrease in the
number of striatal neurons, a change in the cell mor-
phology of neurons in the striatum or cortex, or a
change in the number or size of NIIs following CNTF
administration. Neurons were still capable of gene
expression, insofar as mRNAs were detected in the
hemisphere that received rAAV2-CNTF even though
levels were lower than in the untreated control hemi-
sphere for each animal. It appeared that striatal neurons,
although present, were malfunctioning. Taken together,
these data indicate that sustained expression of CNTF
altered normal gene expression in the striatum of WT
and R6/1 transgenic mice. In fact, for each mRNA
tested, CNTF had a negative impact on gene expression
regardless of the expression of mutant huntingtin. How
CNTF expression mediates changes in neuronal gene
expression and how these changes might ultimately affect
the function of striatal neurons in the HD brain is not
clear at this point.
At the phenotypic level, development and progres-
sion of abnormal behaviors started to occur at 12 weeks
of age, or 2 weeks postsurgery, in the rAAV2-CNTF-
treated R6/1 HD transgenic mice, as opposed to the
typically observed age of onset, which is between 16 and
20 weeks in this strain of mice (Mangiarini et al., 1996).
The WT mice also experienced abnormal behaviors such
as clasping and piloerection commencing at 14 weeks of
age, 4 weeks after they had been injected with rAAV2-
CNTF. Abnormal behaviors have not been observed
previously in WT mice of this strain. The performance
of the rAAV2-CNTF-treated R6/1 HD transgenic mice
on the rotarod was impeded, in that the mice were
unable to remain on the rotating bar as long as age-
matched treated WT, untreated WT, or untreated R6/1
mice. Contrary to our initial hypothesis, it appeared that
continuous striatal overexpression of CNTF at the levels
mediated by rAAV2 transduction exacerbated the devel-
opment of abnormal motor behaviors in R6/1 HD
transgenic mice. Moreover, the development of abnor-
mal phenotype in the treated WT mice suggests CNTF-
mediated toxic effects that are independent of mutant
huntingtin expression. Similar toxic effects were
observed following the delivery of a lentivirus overex-
pressing CNTF in a mouse with a yeast artificial chro-
mosome expressing an expanded (Q72), full-length
human huntingin gene (Zala et al., 2004). Striatal
CNTF overexpression induced both abnormal patterns
of striatal transcription and behavioral abnormalities, sug-
gesting that striatal transcripts are a reasonable indicator
of basal ganglia dysfunction in mice but not necessarily a
causal etiological factor (Denovan-Wright et al., 2007).
However, the precise mechanisms of CNTF overexpres-
sion-induced molecular and/or behavioral abnormalities
are not clear, and the data presented here do not eluci-
date any mechanism.
The use of CNTF for the treatment of HD, and
other neurodegenerative diseases, is considered to have
therapeutic potential. In a phase I clinical trial (Bloch
et al., 2004), six HD patients received an intraventricular
implant of a capsule that contained cells from a BHK
cell line that had been engineered to express and release
CNTF. Levels of CNTF being released from the capsule
prior to implantation ranged from 47 to 619 ng/ml. Im-
mediately after removal, only 11 of 24 capsules secreted
detectable levels (>10 ng/ml) of CNTF, and the 13
other capsules secreted between 15 and 98 ng/ml
CNTF. Levels of secreted CNTF were consistently
lower after the capsules had been in patients for 6
months compared with the initial measurements
obtained (Bloch et al., 2004). None of the patients
treated in this study experienced weight loss, as had
been previously documented in other studies (Miller
et al., 1996; Ettinger et al., 2003; Vergara and Ramirez,
2004; Kokoeva et al., 2005), nor did they experience
any other adverse effects. However, comparison of pre-
operative and postoperative motor, neuropsychological,
and neurological assessments indicated that there was no
statistically significant benefit of the intrathecal release of
CNTF, suggesting that the levels of CNTF remained
below those required for therapeutic benefit. The length
of time for which CNTF was secreted and the steady-
state brain levels of CNTF after implantation of BHK
cells are unknown. The basis of the remarkable lack of
adverse effects observed in this capsule-implantation trial
are not clear, although it is possible that the sustained
steady-state levels of CNTF achieved following implan-
tation of BHK cells were significantly lower compared
with those obtained after systemic administration or after
the use of virally mediated (rAAV or lentivirus) intra-
cerebral delivery.
Our data suggest that, despite the reported neuro-
protective effects of CNTF in chemically induced mod-
els of striatal lesions, expression of CNTF in genetic
models of HD does not prevent mutant huntingtin-
induced transcriptional or behavioral abnormalities.
More importantly, continuous CNTF expression in the
striatum of R6/1 mice exacerbated mutant huntingtin
toxicity and induced mutant huntingtin-like toxicities in
otherwise healthy mice. Different signaling pathways
may regulate a differential CNTF response to toxic
insults that are induced by chemical or genetic
approaches, and this may underlie dissimilarities observed
between the two models. Despite the negative effects of
CNTF observed in this study, this does not rule out the
use of rAAV vectors that produce lower levels of CNTF
in a regulated and/or an intermittent fashion to obtain
the therapeutic benefits obtained using other delivery
methods in HD models . The development of such
regulated rAAV-CNTF vectors could result in lower
adverse effects and ultimately offer some therapeutic
benefit in the HD clinic.
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